European Archives - Page 743 of 1169 - European Medical Journal

IL-23 Inhibition: From Pathophysiological Jungle to Clinical Clearance

The symposium “IL-23 Inhibition: From Pathophysiological Jungle to Clinical Clearance” took place during the 2019 annual European Academy of Dermatology…

Latest Highlights from Guselkumab in Psoriasis from EADV 2019

Guselkumab was the first monoclonal antibody targeting the p19 subunit of IL-23 (IL-23p19) to be approved for the treatment of psoriasis.

Management of Moderate-to-Severe Atopic Dermatitis in the Era of Targeted Treatments

Prof Augustin opened the symposium by underlining how the management of patients with moderate-to-severe atopic dermatitis (AD) has become more dynamic…

Improving Intravenous Immunoglobulin Dosing in Autoimmune Neuropathies

This symposium took place on Monday 24th June 2019, as part of the 2019 Peripheral Nerve Society (PNS) Annual Meeting in Genoa, Italy.

Anticipate Your Next Move in Chronic Myeloid Leukaemia Patient Management

Treatment decisions in chronic myeloid leukaemia (CML) are complex and require the evaluation of many factors at each stage of therapy…

Integrating Selective Targeted Monoclonal Antibody Therapies for Improved Outcomes in Uncontrolled Asthma

Atypical production of several Th2 cytokines, including IL-4, IL-5, and IL-13, play a central pathogenic role in multiple atopic conditions.

European Medical Journal 4.4 2019

EMJ 4.4 is a celebration of triumphant advancements throughout an outstanding year and our spirited elves have been working hard to ensure the year goes out with a festive bang.

Editor's Pick: Identifying Shared Features and Addressing Common Challenges in Clinical Trials for Chronic Inflammatory Diseases: An Overview

Chronic inflammatory diseases (CID) encompass a wide range of pathologies affecting different organs or bodily functions…

Clustering by Health Professionals in Individually Randomised Controlled Trials

Researchers that individually randomised controlled trials (iRCT) assume that the observed outcomes of participants…

Immunotherapy and Oral Immunotherapy with Omalizumab for Food Allergies

Food allergy is potentially life-threatening and has a major impact on quality of life. Avoidance is currently the only approved therapy, and, although…